Prostate Cancer Daily

August 20, 2024

Videos

Peer-to-Peer Clinical Conversations

PROMISE Criteria: Enhanced Survival Prediction in Prostate Cancer with PSMA PET - Wolfgang Fendler

Wolfgang Fendler

Phillip Koo interviews Wolfgang Fendler about advancements in PSMA PET imaging and its prognostic capabilities.

Operationalizing and Coordinating Lutetium-177 PSMA Treatment: Roles of a Multidisciplinary Prostate Cancer Team - Kristen Davis & Sarah Yenser Wood

Dan George discusses the collaborative effort in managing PLUVICTO® therapy for prostate cancer with team members Kristen Davis, a Physician Assistant, and Sarah Wood, a Nurse Practitioner.

Beyond the Abstracts

A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer - Beyond the Abstract

Climate Change Perception and Its Impact on Cancer Screening Intent - Beyond the Abstract

Conference Coverage

SNMMI 2024: Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with Metastatic Castration-Resistant Prostate Cancer (PSMAfore)

ASCO 2024: Discovery of a Novel Non-Negative Matrix Factorization-Based Homologous Recombination Deficiency Score and Subsequent Exploration in TALAPRO-2

APCCC 2024: Lancet Commission on Prostate Cancer– the Forthcoming Surge in Prostate Cancer Raises Very Different Issues to the Ones We Face Today

SESAUA 2024: Darolutamide, Enzalutamide, and Apalutamide for Non-Metastatic Castration-Resistance Prostate Cancer Patients in the United States (DEAR): Comparative Real-World Evidence

ASCO GU 2024: Phase 1b/2 Study of Pembrolizumab Plus Belzutifan and Belzutifan Alone in Patients with Docetaxel-treated mCRPC: KEYNOTE-365 Cohort J

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Evaluation of prostate cancer detection using micro-ultrasound versus MRI through co-registration to whole-mount pathology.

Update on PI-RADS Version 2.1 Diagnostic Performance Benchmarks for Prostate MRI: Systematic Review and Meta-Analysis.

Should Only Patients with BRCA Mutation Be Treated with a Combination of an Androgen Receptor Pathway Inhibitor and a PARP Inhibitor for Metastatic Castration-resistant Prostate Cancer? The Answer Is No.

Long noncoding RNA EPCART regulates translation through PI3K/AKT/mTOR pathway and PDCD4 in prostate cancer.

Olaparib monotherapy or in combination with abiraterone for treating mutated metastatic castration-resistant prostate cancer: alone or stronger together?

Recovery of Social Continence and Sexual Function in Men With High-risk Prostate Cancer after Radical Prostatectomy: Results From a Statewide Collaborative - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC